MX2009011843A - Dosificacion intravenosa y oral de un inhibidor de p2y12 de accion directa y reversible. - Google Patents
Dosificacion intravenosa y oral de un inhibidor de p2y12 de accion directa y reversible.Info
- Publication number
- MX2009011843A MX2009011843A MX2009011843A MX2009011843A MX2009011843A MX 2009011843 A MX2009011843 A MX 2009011843A MX 2009011843 A MX2009011843 A MX 2009011843A MX 2009011843 A MX2009011843 A MX 2009011843A MX 2009011843 A MX2009011843 A MX 2009011843A
- Authority
- MX
- Mexico
- Prior art keywords
- reversible
- intravenous
- inhibitor
- acting
- direct
- Prior art date
Links
- 239000002172 P2Y12 inhibitor Substances 0.000 title 1
- 238000001990 intravenous administration Methods 0.000 title 1
- 230000002441 reversible effect Effects 0.000 title 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 abstract 1
- 229960001138 acetylsalicylic acid Drugs 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003527 fibrinolytic agent Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000006965 reversible inhibition Effects 0.000 abstract 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 abstract 1
- 229960000103 thrombolytic agent Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Emergency Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US91564907P | 2007-05-02 | 2007-05-02 | |
| US94792107P | 2007-07-03 | 2007-07-03 | |
| PCT/US2008/062518 WO2008137753A2 (en) | 2007-05-02 | 2008-05-02 | Intravenous and oral dosing of a direct-acting and reversible p2y12 inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2009011843A true MX2009011843A (es) | 2010-04-22 |
Family
ID=39587015
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2009011843A MX2009011843A (es) | 2007-05-02 | 2008-05-02 | Dosificacion intravenosa y oral de un inhibidor de p2y12 de accion directa y reversible. |
Country Status (17)
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA017402B1 (ru) * | 2005-11-03 | 2012-12-28 | Портола Фармасьютикалз, Инк. | [4-(6-галоген-7-замещенные-2,4-диоксо-1,4-дигидро-2н-хиназолин-3-ил)фенил]-5-хлортиофен-2-илсульфонилмочевины, их формы, способы получения соединений, фармацевтические композиции, содержащие эти соединения, и их применение |
| BRPI0808422A2 (pt) * | 2007-03-06 | 2015-06-23 | Novartis Ag | Compostos orgânicos bicíclicos adequados para o tratamento de condições inflamatórias ou alérgicas |
| CN101720324A (zh) * | 2007-05-02 | 2010-06-02 | 波托拉医药品公司 | [4-(6-氟-7-甲基氨基-2,4-二氧代-1,4-二氢-2h-喹唑啉-3-基)-苯基]-5-氯-噻吩-2-基-磺酰基脲盐、其相关的形式和方法 |
| US20090156620A1 (en) * | 2007-05-02 | 2009-06-18 | Portola Pharmaceuticals, Inc. | [4-(6-fluoro-7-methylamino-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylurea salts, forms and methods related thereto |
| US9427448B2 (en) * | 2009-11-11 | 2016-08-30 | The Medicines Company | Methods of treating, reducing the incidence of, and/or preventing ischemic events |
| CN106075455A (zh) * | 2008-12-30 | 2016-11-09 | 丹麦国家医院 | 鉴定发展成器官功能衰竭的风险提高的危重患者的方法及用于其治疗的化合物 |
| US10376532B2 (en) | 2009-11-11 | 2019-08-13 | Chiesi Farmaceutici, S.P.A. | Methods of treating, reducing the incidence of, and/or preventing ischemic events |
| DK2498731T3 (da) | 2009-11-11 | 2020-03-02 | Chiesi Farm Spa | Fremgangsmåder til behandling eller forebyggelse af stenttrombose |
| CA2785487C (en) * | 2009-12-23 | 2017-11-28 | Ratiopharm Gmbh | Solid pharmaceutical dosage form of ticagrelor |
| US20130165459A1 (en) | 2010-01-12 | 2013-06-27 | Norvartis Pharma Ag | Pharmaceutical composition and dosage forms of elinogrel and methods of use thereof |
| WO2011137459A1 (en) * | 2010-04-30 | 2011-11-03 | Portola Pharmaceuticals, Inc. | Dosage forms of elinogrel and methods of injectable administration thereof |
| WO2012072743A1 (en) * | 2010-12-01 | 2012-06-07 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method and kits for determining platelet susceptibility to activation in a patient |
| US8987285B2 (en) * | 2010-12-03 | 2015-03-24 | Portola Pharmaceuticals, Inc. | Pharmaceutical compositions, dosage forms and new forms of the compound of formula (I), and methods of use thereof |
| MX393334B (es) | 2017-03-15 | 2025-03-24 | Idorsia Pharmaceuticals Ltd | Administración subcutánea de un antagonista del receptor p2y12. |
| MA49452A (fr) | 2017-06-23 | 2021-05-05 | Chiesi Farm Spa | Procédé de prévention de thrombose de shunt de l'artère systémique-pulmonaire |
| CN107462648B (zh) * | 2017-08-21 | 2019-09-27 | 盐城锦明药业有限公司 | 一种Cangrelor中间体腺苷-2-硫酮的高效液相色谱检测方法 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6906063B2 (en) | 2000-02-04 | 2005-06-14 | Portola Pharmaceuticals, Inc. | Platelet ADP receptor inhibitors |
| EA017402B1 (ru) | 2005-11-03 | 2012-12-28 | Портола Фармасьютикалз, Инк. | [4-(6-галоген-7-замещенные-2,4-диоксо-1,4-дигидро-2н-хиназолин-3-ил)фенил]-5-хлортиофен-2-илсульфонилмочевины, их формы, способы получения соединений, фармацевтические композиции, содержащие эти соединения, и их применение |
-
2008
- 2008-05-02 WO PCT/US2008/062518 patent/WO2008137753A2/en not_active Ceased
- 2008-05-02 EA EA200901473A patent/EA200901473A1/ru unknown
- 2008-05-02 MX MX2009011843A patent/MX2009011843A/es not_active Application Discontinuation
- 2008-05-02 KR KR1020097025059A patent/KR20100029746A/ko not_active Withdrawn
- 2008-05-02 CA CA002686203A patent/CA2686203A1/en not_active Abandoned
- 2008-05-02 EP EP08747561A patent/EP2079464A2/en not_active Withdrawn
- 2008-05-02 AU AU2008247483A patent/AU2008247483A1/en not_active Abandoned
- 2008-05-02 BR BRPI0811476-5A2A patent/BRPI0811476A2/pt not_active IP Right Cessation
- 2008-05-02 US US12/114,630 patent/US20090048216A1/en not_active Abandoned
- 2008-05-02 CN CN200880023071A patent/CN101795682A/zh active Pending
- 2008-05-02 JP JP2010506688A patent/JP2010526101A/ja not_active Withdrawn
-
2009
- 2009-10-29 IL IL201834A patent/IL201834A0/en unknown
- 2009-10-30 TN TNP2009000451A patent/TN2009000451A1/fr unknown
- 2009-10-30 GT GT200900284A patent/GT200900284A/es unknown
- 2009-11-26 MA MA32377A patent/MA31663B1/fr unknown
- 2009-12-02 EC EC2009009778A patent/ECSP099778A/es unknown
- 2009-12-02 CO CO09137697A patent/CO6241104A2/es not_active Application Discontinuation
-
2011
- 2011-09-16 US US13/235,305 patent/US20120009172A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP2079464A2 (en) | 2009-07-22 |
| IL201834A0 (en) | 2010-06-16 |
| KR20100029746A (ko) | 2010-03-17 |
| GT200900284A (es) | 2012-01-31 |
| CA2686203A1 (en) | 2008-11-13 |
| ECSP099778A (es) | 2010-01-29 |
| EA200901473A1 (ru) | 2010-06-30 |
| CO6241104A2 (es) | 2011-01-20 |
| BRPI0811476A2 (pt) | 2014-11-04 |
| US20090048216A1 (en) | 2009-02-19 |
| CN101795682A (zh) | 2010-08-04 |
| TN2009000451A1 (en) | 2011-03-31 |
| JP2010526101A (ja) | 2010-07-29 |
| WO2008137753A2 (en) | 2008-11-13 |
| AU2008247483A1 (en) | 2008-11-13 |
| WO2008137753A3 (en) | 2009-02-12 |
| MA31663B1 (fr) | 2010-09-01 |
| US20120009172A1 (en) | 2012-01-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2009011843A (es) | Dosificacion intravenosa y oral de un inhibidor de p2y12 de accion directa y reversible. | |
| ECSP099376A (es) | Inhibidores de la actividad de la akt | |
| HN2009003002A (es) | Compuestos de piridopirimidinonas inhibidores de pi3k-alfa | |
| PL1986669T3 (pl) | Zastosowanie Bifidobacterium longum do zapobiegania i leczenia zapalenia | |
| MX2015012432A (es) | Inhibidores piridinicos de la cinasa cdk9. | |
| IL211825A (en) | Compounds based on pyridine and pyrimidine for use as wnt signal transducer inhibitors, pharmaceutical formulations containing such compounds and used as drugs for the treatment and / or cancer prevention | |
| HRP20110451T1 (hr) | Upotreba izotiocijanata kao sredstva protiv mieloma | |
| MA33803B1 (fr) | Inhibiteur de bromodomaine de benzodiazépine | |
| MX341212B (es) | Inhibidor de bromodominio de benzodiazepina. | |
| MX2009011578A (es) | 6-fenilpirimidinonas como moduladores de pim. | |
| NI200700320A (es) | Inhibidores de la actividad akt | |
| MX2009004017A (es) | Usos de los compuestos carboxi-amido triazol y sus sales. | |
| PH12013500467A1 (en) | Pharmaceutical composition | |
| CL2013001136A1 (es) | Un agente inhibitorio de la fosfodiesterasa 7 (pde7) para ser usado en el tratamiento o la reduccion de la posibilidad de una adiccion; y composicion farmaceutica, forma de dosificacion unitaria y kit farmaceutico que incluyen al inhibidor de fosfodiesterasa 7 (pde7) y un agente terapeutico adicional. | |
| PH12014500386A1 (en) | Combination treatment for hepatitis c | |
| MY177741A (en) | Pharmaceutical compositions compring 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one-lactate monohydrate. | |
| UA109290C2 (uk) | Спільні кристали і солі інгібіторів ccr3 | |
| MY140514A (en) | Triazolopyridine derivatives as inhibitors of lipases and phospholipases | |
| EP2137175A4 (en) | NOVEL PHENANTHRENNEQUINONE-BASED COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME FOR THE TREATMENT OR PREVENTION OF METABOLIC SYNDROME INVOLVING DISEASES | |
| UA93709C2 (ru) | 12-имидазолил-1-додеканол и его применение b изготовлении фармацевтических композиций | |
| PH12013500695A1 (en) | Pharmaceutical compositions containing a dgat1 inhibitor | |
| IN2012DN03428A (cg-RX-API-DMAC7.html) | ||
| MX2010005714A (es) | Compuestos de piridina. | |
| NO20085317L (no) | Imidazoazepinonforbindelser | |
| AR063027A1 (es) | Derivados de sulfonamida |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |